Breaking News

Emergent Names Management for Spin-off

January 21, 2016

Bioscience company Aptevo Therapeutics to be operational mid-2016

Emergent BioSolutions has announced the executive management team of Aptevo Therapeutics, Emergent’s planned biosciences business spin-off company. Members of the Aptevo executive management team will be appointed to their positions effective upon completion of the tax-free spin-off of Aptevo, expected to occur in mid-2016.

“We are pleased to have such an experienced and talented group of individuals to lead Aptevo Therapeutics,” said Daniel Abdun-Nabi, president and chief executive officer, Emergent BioSolutions. “These individuals possess the expertise, commitment and passion to build on the successes of Emergent’s biosciences business for it to grow as a stand-alone publicly-traded company.”

As previously announced, Marvin White will serve as Aptevo’s chief executive officer. He will be joined on the executive management team by the following individuals: Jeff Lamothe, senior vice president and chief financial officer; Scott Stromatt, chief medical officer and senior vice president, clinical development and medical affairs; Jane Gross, vice president, research and non-clinical development; Mike Adelman, vice president, commercial operations; and Shawnte Mitchell, vice president and general counsel.

“The selected management team and I share the same enthusiasm about what Aptevo can accomplish within the immuno-oncology field,” said Mr. White. “We look forward to applying our innovative Adaptir technology to provide novel oncology and hematology therapeutics that could meaningfully improve patients’ lives.”